[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Humanitas Hospital, Italy\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100628731","radiofrequency-ablation-multicenter-observational-study-in-renal-oncology-patients-100628731",false,"NCT07465458","Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients","RASROP-003","Patient selection criteria will be those typically established by each participating center t with T1a primary renal tumors for which a Multidisciplinary Tumor Board has indicated as candidates for treatment with radiofrequency ablation.I\n\nInclusion Criteria:\n\n* Age ≥18 years\n* Signed informed consent approved by the Ethics Committee prior to the ablation procedure.\n* RCC in stage T1a (size \\\u003C4 cm), single or multiple, histologically demonstrated by percutaneous biopsy before or within 30 days prior to ablation\n* Absence of comorbidities that contraindicate treatment\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2 at baseline screening.\n\nExclusion Criteria:\n\n* No specific exclusion criteria are established for this clinical registry due to its observational nature. Each center will apply its own criteria according to its routine clinical practice.","ALL","18 Years",{"count":19,"type":20},226,"ESTIMATED","12 Months","OBSERVATIONAL","This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell carcinomas in stage T1a. All interventions and subsequent follow-ups are clinical decisions are independent of the study, given its observational nature.",[25],"Renal Carcinoma","NOT_YET_RECRUITING","2026-03-12",{"date":29,"type":30},"2026-03-16","ACTUAL",{"date":32,"type":20},"2026-03",{"date":34,"type":20},"2028-06",{"name":36,"class":37},"Humanitas Hospital, Italy","OTHER",10,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100406352","para-aortic-lymphnodes-removal-during-upfront-pancreaticoduodenectomy-100406352","NCT04571294","Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy","Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoa: Should it be Performed? A Multicentre Randomized Controlled Trial.","PALN","Inclusion Criteria:\n\n* pre-operative radiological or histological diagnosis of pancreatic head PDAC, including PDAC arising from IPMN (invasive-IPMN) (in case of not confirmation of PDAC at final pathological examination, the case will be considered as a \"drop out\" and excluded from the study);\n* upfront PD associated with standard lymphadenectomy.\n\nExclusion Criteria:\n\n* PD performed after neoadjuvant treatment;\n* PALN metastases diagnosed by a pre-operative PET-FDG (if performed);\n* intraoperative distant metastases;\n* R2 resection.",{"count":48,"type":20},180,"INTERVENTIONAL",[51],"NA","Pancreaticoduodenectomy (PD) associated with lymphadenectomy is the only curative option for patients affected by pancreatic ductal adenocarcinoma (PDAC). In 2014, the International Study Group on Pancreatic Surgery (ISGPS) defined the \"standard lymphadenectomy\", that is mandatory during PD for PDAC. Lymphadenectomy should include the removal of the hepatoduodenal ligament nodes (stations 5, 6, 12b1, 12b2, 12c according the classification of Japanese Pancreas Society), nodes along the hepatic artery (station 8a), the posterior surface of the pancreatic head (station 13a and 13b), the superior mesenteric artery (14a right lateral side, 14b right lateral side) and nodes of the anterior surface of the pancreatic head (stations 17a and 17b). The inclusion of para-aortic lymphnodes (PALN) (station 16) in standard lymphadenectomy is still matter of debate. Moreover, some retrospectives or prospective studies reported that the presence of PALN metastases has a significant negative prognostic impact. Until now, no randomized studies comparing PD associated with standard lymphadenectomy with or without removal of PALN have been published. The aim of this study is to evaluate if the removal of station 16 should be routinely included in standard lymphadenectomy during PD for PDAC.",[54,55,56],"Pancreas Cancer","Pancreaticoduodenal Lymphadenopathy","Pancreas Adenocarcinoma","RECRUITING","2024-10-02",{"date":60,"type":30},"2024-10-04",{"date":62,"type":30},"2020-05-26",{"date":64,"type":20},"2025-05-31",{"name":36,"class":37},1,""]